Cancer Research and Treatment

Takayuki Asato

1 Article

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study: Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi; Cancer Res Treat. 2018;50(2):398-404. Published online May 10, 2017; DOI: https://doi.org/10.4143/crt.2017.074

Purpose
This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma expressing guanylyl cyclase C (GCC).
Materials and Methods
Adult patients with advanced GI malignancies expressing GCC (H-score ≥ 10) received TAK-264 on day 1 of 3-week cycles as 30-minute intravenous infusions for up to 1 year or until disease progression or unacceptable toxicity. The primary objectives were to evaluate the safety profile including dose-limiting toxicities (DLTs) during cycle 1, determine the maximum tolerated dose (MTD), and characterize the PK profile of TAK-264.
Results
Twelve patients were enrolled and treated with 1.2 mg/kg (n=3), 1.5 mg/kg (n=3), or 1.8 mg/kg TAK-264 (n=6). Median number of treatment cycles received was two (range, 1 to 10). None of the patients experienced a DLT and the MTD was not determined. Ten patients (83%) experienced adverse events (AEs). The most common were neutropenia, anorexia, and nausea (each reported by four patients). Five patients (42%) experienced grade ≥ 3 AEs consisting of tumor hemorrhage and hypertension, ascites, adrenal insufficiency, neutropenia and asthenia. Serum exposure to TAK-264 increased proportionally with the dose and the median half-life was approximately 5.5-6.6 days. No patients experienced an objective response.
Conclusion
TAK-264 demonstrated a manageable safety profile with limited antitumor activity consistent with studies conducted in Western patients with advanced GI malignancies. TAK-264 exposure increased proportionally with the dose.

Citations

Citations to this article as recorded by

Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets
P. Ntellas, A. Athauda, K. Sugiyama, M.L. Le, V. Crespi, I. Chau
ESMO Gastrointestinal Oncology.2025; 8: 100154. CrossRef
Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates
Qingling Yin, Yanlong Zhang, Xueqing Xie, Meijun Hou, Xunsheng Chen, Jie Ding
Cell Death Discovery.2025;[Epub] CrossRef
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
Jia-Lin Hao, Xin-Yun Li, Yu-Tong Liu, Ji-Xuan Lang, Di-Jie Liu, Chun-Dong Zhang
Gastric Cancer.2024; 27(5): 887. CrossRef
Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo
Karthik Venkatakrishnan, Neeraj Gupta, Patrick F. Smith, Tiffany Lin, Neil Lineberry, Tatiana Ishida, Lin Wang, Mark Rogge
Clinical Pharmacology & Therapeutics.2023; 113(2): 298. CrossRef
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
Richard Kim, Alexis D. Leal, Aparna Parikh, David P. Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M. Cleary
Cancer Chemotherapy and Pharmacology.2023; 91(4): 291. CrossRef
Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature
Moein Piroozkhah, Ali Aghajani, Pooya Jalali, Arvin Shahmoradi, Mobin Piroozkhah, Younes Tadlili, Zahra Salehi
Frontiers in Oncology.2023;[Epub] CrossRef
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
Claudia Ceci, Pedro Miguel Lacal, Grazia Graziani
Pharmacology & Therapeutics.2022; 236: 108106. CrossRef
Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
Na Wang, Qingyun Mei, Ziwei Wang, Lu Zhao, Dou Zhang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Yingjie Jia, Fanming Kong
Frontiers in Oncology.2022;[Epub] CrossRef
Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development
Davinder Singh, Divya Dheer, Abhilash Samykutty, Ravi Shankar
Journal of Controlled Release.2021; 340: 1. CrossRef

9,940 View
218 Download
10 Web of Science
9 Crossref

Author index